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The evidence of an association between Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome (ME/CFS) and chronic herpesviruses infections remains inconclusive. Two
reasons for the lack of consistent evidence are the large heterogeneity of the patients’
population with different disease triggers and the use of arbitrary cutoffs for defining
seropositivity. In this work we re-analyzed previously published serological data related
to 7 herpesvirus antigens. Patients with ME/CFS were subdivided into four subgroups
related to the disease triggers: S0-42 patients who did not know their disease trigger;
S1-43 patients who reported a non-infection trigger; S2-93 patients who reported an
infection trigger, but that infection was not confirmed by a lab test; and S3-48 patients
who reported an infection trigger and that infection was confirmed by a lab test. In
accordance with a sensitivity analysis, the data were compared to those from 99 healthy
controls allowing the seropositivity cutoffs to vary within a wide range of possible values.
We found a negative association between S1 and seropositivity to Epstein-Barr virus
(VCA and EBNA1 antigens) and Varicella-Zoster virus using specific seropositivity cutoff.
However, this association was not significant when controlling for multiple testing. We
also found that S3 had a lower seroprevalence to the human cytomegalovirus when
compared to healthy controls for all cutoffs used for seropositivity and after adjusting for
multiple testing using the Benjamini-Hochberg procedure. However, this association did
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not reach statistical significance when using Benjamini-Yekutieli procedure. In summary,
herpesviruses serology could distinguish subgroups of ME/CFS patients according to
their disease trigger, but this finding could be eventually affected by the problem of
multiple testing.
Keywords: disease trigger, cutoff value, stratification, Epstein-Barr virus, human cytomegalovirus, varicella-zoster
virus, human herpesvirus-6, herpes simplex virus 1 and 2
INTRODUCTION
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
(ME/CFS) is a complex disease with unknown cause whose
patients experience persistent fatigue that cannot be alleviated
by rest and suffer from post-exertional malaise upon minimal
physical and/or mental activity (1). Disease prevalence has
been estimated around 0.4% after pooling data from different
epidemiological studies (2). However, this estimate might
be conservative (3, 4) due to poor societal recognition of
the disease including amongst health professionals (5), the
inexistence of an objective disease-specific biomarker for the
corresponding diagnosis (6), a small number of well-designed
epidemiological studies (7), and limited funding opportunities
for more comprehensive and integrative research (8).
The etiology of ME/CFS and its pathogenesis remains a topic
under intense debate with the proposal of many competing
hypotheses (9–16). However, there is a general consensus that
the disease could be initiated by a combination of genetic
predisposing factors (17–20) and environmental triggers (e.g.,
exposure to toxins, chronic emotional and physical stress)
(10, 21). In this regard, a large proportion of patients report
an acute infection at the onset of their symptoms (22, 23).
Herpesviruses such as the Epstein-Barr virus (EBV) and the
human herpesvirus-6 (HHV6) were considered to be the main
candidates for the causative agents of ME/CFS due to their
high prevalence in adults and their reactivation observed in
patients (11, 24, 25). To understand the role of these viruses
on ME/CFS, many serological investigations were conducted
with inconclusive or even contradicting findings (24). Possible
reasons for this contrasting evidence could be related to disease
misclassification and selection bias (26, 27), the necessity of
dividing patients into different subtypes (28), the low number
of patients recruited (6), or differences in the antigen and
experimental assays used (29). An additional but often ignored
reason is that serological studies are typically based on arbitrary
cutoff values for identifying seropositive individuals or high
antibody responders, as illustrated in two serological studies on
herpesviruses (30, 31).
Recently, the analysis of serological data from the
United Kingdom ME/CFS Biobank (UKMEB) did not find
any association between ME/CFS and the presence of antibodies
against chronic infections by different herpesviruses (32). In this
work, we re-analyzed these data by dividing the ME/CFS patients
into four subgroups related to non-infection vs. infection
disease triggers. We also performed a sensitivity analysis of the
association between ME/CFS and each herpesvirus as a function
of the cutoff defining seropositivity.
MATERIALS AND METHODS
Study Participants
All study participants are part of the UKMEB as described before
(33). In summary, the data refer to a cohort of 226 patients with
ME/CFS and 99 healthy controls (HC); note that the sample size
of the healthy controls is in line with the ones used for this group
by current serological studies on the role of herpesviruses on
ME/CFS, as summarized elsewhere (24). At biobank enrollment,
patients had to fill in a symptom’s assessment questionnaire in
which they were asked a specific question about whether they
had an infection at the disease onset. This question had four
categories of response, which we used to divide the patients into
the following subgroups: subgroup S0– she/he did not know
whether she/he had an infection at the disease onset (n =
42, 18.5%); subgroup S1– she/he did not have an infection at
the disease onset (n = 43, 18.9%); subgroup S2– she/he had
an infection at the disease onset, but this infection was not
confirmed with a lab test (n = 93, 41.0%); subgroup S3– she/he
had an infection at the disease onset and this infection was
confirmed with a lab test (n = 48, 21.1%). In the participant
questionnaire, patients were also asked to narrate the factors that
could have triggered or contributed to the disease. Given that this
was an open question, we only performed a brief description of
the respective responses.
All individuals had age between 18 and 60 years old. Patients
with ME/CFS were referred for a possible inclusion in the
UKMEB by general practitioners working in the National Health
System (NHS) of the United Kingdom. The respective diagnosis
was confirmed using the 1994 Centers for Disease Control
and Prevention (CDC) (34) or the 2003 Canadian Consensus
Criteria (35) by the UKMEB dedicated clinical research team,
according to their designed clinical protocol (36). Participants
were excluded if they were taking any anti-viral drug or any
medication that could alter their immune function in the
three preceding months. Healthy controls were either family
members or friends of the recruited patients with ME/CFS, or
they were volunteers recruited by advertisement within Higher
Education Institutions. Detailed information about exclusion and
inclusion criteria of the UKMEB and additional information
about recruitment and sample processing can be found elsewhere
(36, 37).
Herpesviruses Serology
Serological data and the respective laboratory procedures were
previously described in the original study (32). However, given
that the main focus of this early study was cellular immunology,
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the description of herpesviruses serology was kept to a minimum.
We have now provided some additional details.
The following commercial ELISA assays from Demeditec
Diagnostics (Kiel, Germany) were used to quantify the plasma
concentrations of IgG antibodies against the following viruses:
the human cytomegalovirus (CMV; Prod. Ref. DECMV01), EBV-
VCA antigen (Prod. Ref. DEEBVG0150), EBV-EBNA1 antigen
(Prod. Ref. DE4246), herpes simplex virus-1 (HSV1; Prod.
Ref. DEHSV1G0500), herpes simplex virus-2 (HSV2; Prod.
Ref. DEHSV2G0540), Varicella-Zoster virus (VZV; Prof. Ref.
DEVZVG0490). The commercial ELISA-VIDITEST fromVIDIA
(Vestec, Czech Republic) was used for the IgG quantification
against HHV6 (Prod. Ref. ODZ-235).
Antibody quantification was expressed in arbitrary units
per milliliter (U/ml). According to manufacturer’s instructions,
seropositivity was considered for all samples with concentration
≥ 12 U/ml for HSV1, HSV 2, VZV, CMV and EBV antigens.
Likewise, individuals with antibody concentrations against
HHV6 ≥ 12.5 U/ml were considered seropositive.
Statistical Analysis
To compare the age of the participants, the age of disease
onset, and the disease duration of different study groups and/or
subgroups of ME/CFS patients, we used the non-parametric
Kruskal-Wallis test. To compare the gender distribution in the
same subgroups, we applied the Pearson’s χ2 test for testing
independence in two-way contingency tables. For simplicity of
the analysis, we only reported frequencies and the respective
percentages of different disease triggers in the subgroups of
ME/CFS that mentioned the occurrence of such triggers.
We previously performed thorough analyses of different cutoff
values for seropositivity to each viral antigen (38, 39). These
earlier analyses were based on the comparison and the selection
of different scale mixtures of skew-normal distributions and four
different criteria to define seropositivity. In accordance with a
sensitivity analysis, instead of selecting a fixed cutoff, we here
allowed this cutoff to vary between 10 U/ml and 100 U/ml with
a lag of 1 U/ml. For each cutoff of a given antibody, we first
estimated the unadjusted seropositivity odds ratio (OR) and the
area under the Receiver Operating Characteristic curve (AUC)
between each ME/CFS subgroup and the healthy controls using
a logistic regression model in which seropositivity status of the
individuals and a group indicator were the outcome and the
covariate, respectively.
We then adjusted these ORs and AUCs using a similar logistic
regressionmodel but including age, gender, and a group indicator
variable as the respective covariates. In both unadjusted and
adjusted analyses, the effect of healthy controls was set as the
reference of the group indicator variable. We calculated the
p-values of the Wald’s score test to assess the significance of
different log-ORs of each subgroup of ME/CFS in relation to
the group of healthy controls. The significance level of each
executed test was set at 5%. In Supplementary File, one can find
a detailed description of the likelihood function of the regression
models used and how the ORs (or the log-ORs) are related to the
parameters of these models.
To investigate the impact of multiple testing on the results,
we adjusted the raw p-values of the Wald’s score tests in order to
ensure a false discovery rate of 5%. With this purpose, we used
the Benjamini-Hochberg (BH) and Benjamini-Yekutieli (BY)
procedures under the assumption of independent and positively
correlated tests, respectively (40, 41). In this analysis, adjusted p
< 0.05 were indicative of statistically significant associations.
Finally, we estimated the statistical power of the detected
associations using a parametric Bootstrap approach (42). For
each antibody, we used the following algorithm: (i) determine
the optimal seropositivity cutoff by maximizing the likelihood
ratio statistic as a function of this parameter when comparing
the above logistic models with and without the group indicator
covariate; (ii) generate the seropositivity data resulting from
the optimal cutoff; (iii) estimate a logistic model including the
group indicator as the only covariate (unadjusted analysis) or
a logistic model including age, gender and group indicator
variables as the respective covariates (adjusted analysis) using
the seropositivity data obtained in (ii); simulate 1,000 data
sets using the seropositive probability estimates obtained from
models fitted in (iii); (iv) calculate the power of the association
between seropositivity and each study group by the proportion
of simulated data sets in which the association was deemed
significant at the 5% significance level using the Wald’s score test
as described above.
The statistical analysis was conducted in the R software
version 4.0.3. In particular, the estimation of the logistic
regression models was done using the “glm” command and the
analysis based on the AUC was conducted using the package
“pROC” (43). In the multiple testing analysis, the raw p-values
were adjusted by the BH and BY procedures using the package
“MASS” (44). The corresponding scripts are available from the
first or the corresponding author upon request.
RESULTS
Basic Characterization of Study
Participants
The four subgroups of ME/CFS had the same age distribution
approximately (Kruskal-Wallis test, p= 0.30) with means of 44.6,
40.7, 43.3, and 40.9 years old for S0, S1, S2, and S3, respectively
(Table 1). The respective mean ages of disease onset were 32.1,
30.2, 31.3, and 27.3 years old, while the mean disease durations
were 12.7, 11.6, 12.1, and 13.5 years for the same subgroups.
The differences in these variables were not statistically significant
(p = 0.55 and 0.21, respectively). Similarly, the percentages of
female patients ranged from 70.8% to 80.6%, but they were not
statistically different (Pearson’s χ2 test, p= 0.62).
Overall, the percentage of severely affected patients
significantly differed among the subgroups (Pearson’s χ2
test, p = 0.003). In particular, the percentage of these patients in
S0 and S1 was approximately 9%. This value was in clear contrast
with the 30% of severely affected patients belonging to S2 and S3,
both groups related to infection triggers.
In terms of the number of narrated disease factors or triggers
reported in the participant’s questionnaire, the subgroup S1 had
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TABLE 1 | Basic characteristics of study participants where patients with ME/CFS were split into four subgroups according to the responses about their disease triggers
in the symptoms’ assessment questionnaire.
Healthy controls
(n = 99)
Subgroups of ME/CFS patients Comparison (P-values)




Female (%) 73 (73.7) 33 (78.6) 33 (76.7) 75 (80.6) 34 (70.8) 0.62 0.69
Mean age (IQR) 41.9 (32–51.5) 44.6 (35.0–53.8) 40.7 (28.0–52.0) 43.3 (35.0–53.0) 40.9 (32.0–50.3) 0.30 0.44
Mean age of disease onset (IQR) 32.1 (21.9–43.5) 30.2 (20.2–39.3) 31.3 (22.1–39.1) 27.3 (18.9–36.2) 0.21 -
Mean disease duration (IQR) - 12.7 (5.30–17.90) 11.6 (4.2–15.9) 12.1 (5.5–16.5) 13.5 (6.0–19.2) 0.55 -
Disease severity at recruitment
Mild/moderate (%) - 38 (90.5) 39 (90.7) 64 (68.8) 34 (70.8) 0.003 -
Severely affected (%) - 4 (9.5) 4 (9.3) 29 (31.2) 14 (29.2) - -
Number of self-reported disease triggers
Single - - 19 (44) 52 (56) 32 (67) <0.001a -
Multiple - - 10 (23) 35 (38) 11 (23) - -
Missing - - 14 (33) 6 (6) 5 (10) - -
S0, Do not know; S1, Non-infection trigger; S2, An infection trigger but not confirmed with a lab test; and S3, An infection trigger confirmed with a lab test.
aPearson’s χ2 test including the missing as a category for the number of disease factors/triggers.
TABLE 2 | Frequency and the respective percentage within brackets of specific
disease factors or triggers narrated by patients from the subgroups S1 (n = 43),
S2 (n = 93), and S3, (n = 48) in the participant’s questionnaire.
Narrated disease trigger Subgroups of ME/CFS
patients
Total (%)
S1 (%) S2 (%) S3 (%)
Glandular Fever; tonsilitis; EBV
infection
1 (2) 25 (27) 22 (46) 48 (21)
Respiratory infection; pneumonia 1 (2) 6 (6) 3 (6) 10 (4)
Flu-like infection or illness 2 (5) 20 (22) 4 (8) 26 (11)
Gastrointestinal infection 0 (0) 6 (6) 3 (6) 9 (4)
Tropical infections 0 (0) 1 (1) 2 (4) 3 (1)
Other infections including
unspecified viral infections
2 (5) 33 (35) 13 (27) 51 (22)
General stress or anxiety 6 (14) 11 (12) 3 (6) 20 (9)
Stress due to personal events 9 (21) 6 (6) 3 (6) 18 (8)
Stress at work or school 4 (9) 5 (5) 2 (4) 11 (5)
Vaccinations 0 (0) 4 (4) 6 (12) 10 (4)
Chemical exposure 1 (2) 6 (6) 0 (0) 7 (3)
Accidents/Injuries/Surgeries 7 (16) 2 (2) 2 (4) 11 (5)
Pregnancy/Childbirth/Postnatal/
Hysterectomy/Endometriosis
6 (14) 0 (0) 0 (0) 6 (3)
Other 4 (9) 6 (6) 0 (0) 7 (3)
the lowest percentage of patients reporting a single factor or
trigger for their disease (44%) when compared to infection-
related subgroups S2 and S3 (56 and 67%, respectively; Table 1).
The same subgroup was the one with the highest percentage of
missing data to this question (33% for S1 vs. 6 and 10% for S2
and S3, respectively). Overall, the distribution of the number
of reported disease factors or triggers was significantly different
among subgroups S1, S2, and S3 (Pearson’s χ
2 test, p < 0.001)
mostly due to differences in the amount of missing data.
These subgroups of ME/CFS patients were well matched
for gender and age with respect to the healthy control
group (Pearson’s χ2 and Kruskal-Wallis tests, p = 0.69 and
0.44, respectively).
Disease Factors or Triggers Narrated by
Different Subgroups of ME/CFS Patients
When the 184 patients belonging to the subgroups S1, S2, and S3
were asked to narrate the factors or triggers of their disease in
the participant questionnaire, 103 (56%) and 56 (30%) of them
reported single and multiple factors (or triggers), respectively.
However, 25 patients (14%) did not mention any specific trigger
or factor contributing to their disease. In total, there were 14
distinct categories of disease triggers narrated by the patients.
These categories were consistent to the ones reported by previous
epidemiological studies about possible triggers of ME/CFS (22,
23).
The following non-infection factors or triggers were
mentioned by patients mostly belonging to the subgroup S1:
stress subdivided into general anxiety (9%, n = 20), personal
(8%, n = 18) or professional-related stress (5%, n = 11);
accidents/injuries/surgeries (5%, n = 11); pregnancy, childbirth
and other problems related to women’s reproduction system
(3%, n = 6), and other non-infection triggers (Table 2). The
remaining factors were related to microbial infections and/or
infectious diseases: upper respiratory tract infections – glandular
fever (GF), tonsillitis, EBV infections, or throat infection (21%,
n = 48); lower respiratory tract infections – chest infection or
pneumonia (4%, n= 10); flu- or cold-like illnesses (11%, n= 26);
gastrointestinal problems and related infections (4%; n= 9); and
tropical infectious diseases – Dengue fever and schistosomiasis
(1%, n= 3); and other viral or bacterial infection, and unspecified
infections (22%, n = 51). Note that 6 patients from subgroup
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S1 mentioned an infection in the narrative question about
the factors or triggers of their disease. However, the same
patients also reported other possible non-infection triggers, such
as trauma, bereavement, and stress. We speculate that these
patients attributed a higher likelihood to these non-infection
disease triggers when answering the related question in the
symptoms’ assessment questionnaire. Interestingly, patients
belonging to the subgroup S3 reported the highest percentage of
disease factors or triggers consistent with an EBV infection (46%,
n = 22). Patients from subgroup S2 also self-reported a high
frequency of EBV-related factors or triggers (27%, n = 25), but
closely matched by a flu-like infection or illness (22%, n= 20).
Serological Data Analysis by Subgroup of
ME/CFS Patients
We then compared the serological data of these ME/CFS
subgroups of patients with the group of healthy controls
(Figure 1). In this analysis, we intended to investigate the
impact of cutoff on the resulting seropositivity OR and AUC
between each subgroup of ME/CFS patients and the group of
healthy controls.
With respect to unadjusted analysis, the AUCs were in most
cases estimated between 0.50 and 0.60 (Figure 2A). This finding
suggested that serological data had limited predictive power
to discriminate the seropositivity of subgroups of ME/CFS
patients from that of healthy controls. The highest estimated
AUC was approximately 0.75 for VZV when comparing the
seropositivity of the subgroup S2 to healthy controls using cutoffs
below 15 U/ml.
According to the OR estimates, we could not find any
significant association of subgroups S0 and S2 with herpesviruses
serology (Figures 2B,C). The only exception was a putative
association between the subgroup S0 and the antibodies against
EBV-VCA using a cutoff of 37 U/ml. Interestingly, before
correcting for multiple testing, we found significant negative
associations (i.e., negative log-ORs) between the subgroup S1 and
antibodies against EBV-VCA, EBV-EBNA1, and VZV depending
on the cutoff used (Figures 2B,C). These negative associations
suggested decreased seroprevalences to these herpesviruses in
this subgroup when compared to the group of healthy controls.
When controlling for multiple testing, these associations were
not considered statistically significant using either BH or BY
procedures (Figures 2D,E).
We also found a significant negative association between
subgroup S3 and CMV seropositivity (Figures 2B,C), which
suggested decreased antibody levels in this subgroup of patients
in relation to group of healthy controls. The corresponding AUC
was estimated around 0.65 for most of cutoffs (Figure 2A). This
association was consistent across the range of cutoffs specified
for the analysis and even after controlling for multiple testing
using the BH procedure based on the assumption of independent
tests (Figure 2D). However, the statistical significance of the
association was lost after using the BY procedure based on the
assumption of positively correlated tests (Figure 2E).
Similar findings were obtained when adjusting
for possible confounding effects of age and gender
(Supplementary Figures 2A–E). This agreement between
unadjusted and adjusted analyses can be explained by a
good matching between the different ME/CFS subgroups
of patients and healthy controls in terms of age and gender
(Table 1). However, the significance of adjusted ORs was
slightly reduced due to these putative confounding factors
(Supplementary Figure 2C).
Finally, we estimated the statistical power related to the
identified associations using the optimal seropositivity cutoff
for each herpesvirus antibody. For the unadjusted analysis,
these optimal cutoffs varied from 11 U/ml to 90 U/ml
(Supplementary Figure 1 and Supplementary Table 1).
Similar optimal cutoffs were obtained for the analysis
adjusting for age and gender (Supplementary Figure 3 and
Supplementary Table 1) with the exception of EBV-EBNA1
for which the optimal cutoffs were 72 U/ml and 88 U/ml
for the unadjusted and adjusted analyses, respectively. The
maximum power (∼90%) was obtained for the association
between CMV seropositivity and ME/CFS subgroup S3 in either
unadjusted or adjusted analyses (Supplementary Figure 4).
A high power (∼75%) was also obtained for the associations
between VZV seropositivity and ME/CFS subgroup S1.
The remaining associations between each study group and
herpesvirus seropositivity had a power that did not exceed
60%. In conclusion, the manufacturer’s seropositivity cutoffs
were not the most adequate to maximize the chance of finding
an association of ME/CFS subgroups with the herpesviruses
serology and only three associations between the study groups
and herpesviruses seropositivity had a high statistical power.
DISCUSSION
In contrast with the original study where we could not find
differences related to herpesviruses serology between healthy
controls and ME/CFS patients divided according to their disease
severity (32), our re-analysis of the same data identified two
subgroups of ME/CFS patients (S1 and S3) in which such
differences are now statistically significant. This new finding was
only possible due to the stratification of patients according to
a question related to the occurrence of an infection at disease
onset together with a sensitivity analysis of the seropositivity
cutoff used. Patients’ stratification or subtyping was performed
in line with past recommendations for ME/CFS research (28).
Following this recommendation, we previously performed an
immunological investigation based on a stratification of ME/CFS
patients according to the severity of their symptoms (32). By
using this stratification, we showed perturbations in the T-cell
compartment, namely, in effector CD8+ T cells and in the
mucosal-associated invariant T cells. In another study using
similar stratification of the samples from the UKMEB, the
levels of the cellular stress biomarker GDF15 were found to be
increased in severely affected patients at different time points
(45). We speculate that other immunological perturbations could
be detected if our alternative stratification could have been used.
This investigation will be carried out in the near future.
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FIGURE 1 | Herpesvirus serology data per study group including the four ME/CFS subgroups. Horizontal dashed lines represent the optimal seropositivity cutoff for
the unadjusted analysis according to the maximization of likelihood ratio statistic for testing the significance of the group indicator covariate in the logistic models (see
Supplementary Figure 1).
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FIGURE 2 | Unadjusted association analysis of seropositivity to different herpesvirus antigens as function of the cutoff defining seropositivity. (A) AUC of the
probabilities of being seropositive estimated in each subgroup of ME/CFS patients when compared to the same probabilities estimated in the group of healthy
controls. (B) Log-ORs of being seropositive in each subgroup of ME/CFS patients in relation to the group of healthy controls. (C) Raw p-values of Wald’s score test for
the significance of log-ORs. (D) The corresponding BH-adjusted p-values. (E) The corresponding BY-adjusted p-values. For convenience, raw and adjusted p-values
were transformed as –log10(p-value). The dashed lines in the respective plots represent the threshold referring to the 5% significance level [i.e., –log10(0.05); C] or the
5% false discovery rate. (D,E) Cutoff values in which –log10(p-values) are above these thresholds provided evidence for significant associations.
In line with our findings, evidence has been emerging that
the occurrence of an acute infection at the onset of disease
symptoms is indeed a key stratifying factor to detect genetic
and immunological differences between subgroups of ME/CFS
patients when compared to healthy controls (17, 46). However,
the simplistic approach of dividing patients according to non-
infection and infection triggers might not be sufficient to
obtain relatively homogeneous subgroups of ME/CFS patients,
which affects the statistical power to detect any disease-specific
effects. Besides the limited choice of antibodies against different
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herpesvirus-related antigens, the large heterogeneity in infectious
triggers seems a possible explanation for the lack of association
between the subgroup S2 and herpesviruses seropositivity.
Notwithstanding not having their infection trigger confirmed
in the lab, patients from this subgroup reported the highest
proportion of flu-like illnesses, which could have been caused by
the influenza virus, the rhinovirus, or the respiratory syncytial
virus (47). It is then conceivable that these patients exhibit
different pathological mechanisms of ME/CFS according to the
causative virus, some of which without any direct impact on
the antibody responses against herpesviruses. To overcome these
problems, we recommend the collection of infection-trigger data
as detailed and accurate as possible.
Our most consistent association was obtained between CMV
seropositivity and patients from the subgroup S3. These patients
tended to be less seropositive to this herpesvirus when compared
to healthy controls, irrespective of the seropositivity cutoff value
used. Previously, different serological investigations did not
provide conclusive evidence for the role of CMV on ME/CFS
pathogenesis, as reviewed elsewhere (24). The lack of or the
use of an inadequate stratification could also explain these past
findings. In this regard, the unveiled association was obtained
in a subgroup in which the accuracy of the reporting might
be the highest, because the disease-triggering infections were
supposedly confirmed in the lab. However, we cannot ignore the
fact that this subgroup has a large fraction of patients whose
disease trigger was related to an EBV infection, one of the most
reported causative agents of ME/CFS. Therefore, it is possible
that our finding resulted from a coincidence between a low-
resolution patient’s stratification and a random enrichment of a
specific infection trigger in one of the subgroups.
A supposedly decreased seropositivity (or antibody levels) to
CMV in an EBV-infection trigger could be explained by the
hyperregulation hypothesis (11). According to this hypothesis,
a possible pathological mechanism of ME/CFS is related to an
expansion of regulatory CD4+ T cells (Tregs) driven by an
autoimmune response against a viral antigen that mimics a self-
antigen. This expansion of Tregs upon herpesvirus infection or
reactivation locks the (adaptive) immune system in an active state
of hyperregulation where different infections are more difficult
to be cleared from the body. Frequent infections are in fact
reported by patients with ME/CFS (33). The question is then
how the expansion of Tregs could affect antibody responses
against CMV. The so-called follicular Tregs might hold the
answer to this question. These specialized Tregs are derived from
Treg precursors with the ability to migrate to germinal center
reactions (GCRs) to inhibit the respective antibody production
and antibody maturation (48). In particular, experiments with
animal models demonstrated that the amount of IgG antibodies
against different foreign antigens is increased in immunized mice
depleted of follicular Tregs (49, 50). In this line of thought, it
is reasonable to assume that an increased proportion of Tregs
in ME/CFS could be translated into an increased proportion of
follicular Tregs. This increase could in turn decrease the antibody
production derived from GCRs. We can then hypothesize that an
EBV infection triggered an autoimmune response that disrupted
the normal balance between Tregs and effector CD4+ T cells;
a peptide of the viral EBNA6 was found to share a high
sequence homology with the human lactoperoxidase and thyroid
peroxidase (30). The disruption of this balance could lead to
an increase of both natural and follicular Tregs. A possible
consequence of this increase is a diminished antibody production
against a posterior CMV infection or reactivation. Note that
several peptides fromCMVwere also found as putative candidate
for molecular mimicry with human proteins (51). Similar to the
situation of immunosuppression, a reduction in the humoral
immunity against CMV would render ME/CFS patients more
susceptible to a possible reactivation of this virus (52). It is worth
noting that the role of follicular Tregs was never investigated
in ME/CFS patients.
Another interesting finding is the possible association between
the subgroup S1 and EBV and VZV seropositivity. This subgroup
refers to patients who reported non-infectious triggers, mostly
related to stressful or stress-related events. It is also a group
where ME/CFS was triggered in many women who had problems
during and after pregnancy, had difficult childbirth or had
disorders related to women’s reproduction system. In line with
this finding, stressful conditions and events such as the ones
experienced by astronauts increase the chance of herpesvirus
reactivation, specifically, EBV, VZV and CMV (53). Reactivation
of latent herpesvirus infections could be explained by an increase
in production of stress-related hormones together with an
inflammatory cytokine signature that debilitates the immune
system. This subgroup is then expected to have a higher
prevalence of active herpesvirus infections than the remaining
subgroups of ME/CFS patients and healthy controls. Given that
this subgroup could represent <50% of the patients (22, 23),
it is likely to have insufficient statistical power to detect any
differences in herpesvirus reactivation rates between ME/CFS
and healthy controls even in the case of a proper stratification
of the patients’ populations. This limitation is yet another reason
that could explain the inconsistent findings on herpesvirus
reactivation across many studies on ME/CFS.
We did not find any association between the subgroup S0 and
herpesviruses seropositivity. This subgroup represented 18.5% of
the patients’ cohort, a value compatible with the percentages of
patients that did not report any disease triggering event from
past epidemiological studies [10%, (22); 24%, (54)]. The sample
size of this subgroup was not very large and, therefore, we
cannot rule out that our lack of associations could be simply
due to insufficient statistical power to detect putative associations
between this subgroup and herpesviruses seropositivity.
In our association analysis, we allowed the seropositivity cutoff
to vary within a given range of possible values, similarly done in
a recent study of molecular mimicry between Anoctamin 2 and
EBNA1 in multiple sclerosis (55). This analytical approach seems
reasonable given the difficulty to choose the best seropositivity
cutoff among the different criteria and methods available, as
illustrated in the earlier analyses of the same data (38, 39).
This approach is also in line with several discussions about
seropositivity estimation and the sensibility to use a fixed cutoff
(56–59). However, varying the cutoffs defining seropositivity
might increase the chance of false positives due to the multiple
testing problem. We attempted to overcome this problem by
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controlling the false discovery rate, but the small sample size
of each subgroup of ME/CFS did not allow to reach statistical
significance of the detected associations when using the BY
procedure based on the assumption of multiple positively
correlated tests. On the other hand, our power calculations
suggested a high probability of detecting some of the associations
under the assumption that they were actually true. Therefore,
the correct application of cutoff-varying approach should include
a thorough assessment of a putative multiple testing problem
together with a power calculation in order to assess the statistical
consistency of the findings.
As final remarks, we should also note that cutoffs for detecting
associations between herpesviruses andME/CFSmight vary from
one lab to another and with the serological kits used. In addition,
a high cutoff for the data might not define seropositivity per
se, but rather a high antibody response whose detection could
be the primary objective of the analysis (30, 31). The use of
a high cutoff is also in accordance with a modeling approach
where seropositivity might be subdivided into different levels
(60–62). Therefore, our sensitivity-like approach seems to have
the capacity to detect further serological associations beyond
the ones based on the classical seroprevalence. Such a capacity
could increase the chance of reaching scientific reproducibility.
We then recommend the routine use of this approach in future
serological investigations of ME/CFS.
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